Spotlight on Patritumab Deruxtecan (HER3-DXd) from HERTHENA Lung01. Is a Median PFS of 5.5 Months Enough in Light of FLAURA-2 and MARIPOSA?
-
Published:2024-07
Issue:
Volume:Volume 15
Page:115-121
-
ISSN:1179-2728
-
Container-title:Lung Cancer: Targets and Therapy
-
language:en
-
Short-container-title:LCTT
Author:
Arter Zhaohui,
Nagasaka MisakoORCID
Publisher
Informa UK Limited
Reference31 articles.
1. The salvage therapy in lung adenocarcinoma initially harbored susceptible EGFR mutation and acquired resistance occurred to the first-line gefitinib and second-line cytotoxic chemotherapy
2. Osimertinib with or without Chemotherapy in EGFR-Mutated Advanced NSCLC
3. MARIPOSA: phase 3 study of first-line amivantamab + lazertinib versus osimertinib in EGFR-mutant non-small cell lung cancer
4. Cho BC, Felip E, Spira A, et al. Amivantamab plus lazertinib versus osimertinib as first-line treatment in EGFR-mutated advanced NSCLC: primary results from MARIPOSA, a Phase 3, global, randomized, controlled trial. ESMO Congress Oct; Madrid, Spain; 2023.
5. Pemetrexed and platinum with or without pembrolizumab for tyrosine kinase inhibitor (TKI)-resistant, EGFR-mutant, metastatic nonsquamous NSCLC: Phase 3 KEYNOTE-789 study.